Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis

European Journal of Cancer

Volumn 48, Issue 15, 2012, Pages 2361-2368

  Monk, Bradley J ^a   Herzog, Thomas J ^b   Kaye, Stanley B ^c   Krasner, Carolyn N ^d   Vermorken, Jan B ^e   Muggia, Franco M ^f   Pujade Lauraine, Eric ^g   Park, Youn C ^h   Parekh, Trilok V ^h   Poveda, Andres M ⁱ  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

ⁱ INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Pegylated liposomal doxorubicin; Recurrent ovarian cancer; Trabectedin

Indexed keywords

DOXORUBICIN; TRABECTEDIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIOXOLES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; TETRAHYDROISOQUINOLINES;

EID: 84866736948     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.04.001     Document Type: Article

References (28)

1. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
2. P.G. Rose, S. Nerenstone, and M.F. Brady Secondary surgical cytoreduction for advanced ovarian carcinoma N Engl J Med 351 2004 2489 2497
3. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynaecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
4. D.K. Armstrong, B. Bundy, and L. Wenzel Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
5. I. Vergote, C.G. Trope, and F. Amant Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
6. S. Aebi, and M. Castiglione Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl. 4 2009 21 23
7. R.J. Morgan Jr., R.D. Alvarez, and D.K. Armstrong Ovarian cancer. Clinical practice guidelines in oncology J Natl Compr Cancer Netw 6 2008 766 794
8. S.A. Cannistra Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol 28 2010 3101 3103
9. M.K. Parmar, J.A. Ledermann, and N. Colombo Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2003 2099 2106
10. A.N. Gordon, M. Tonda, and S. Sun Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomised study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 95 2004 1 8
11. J. Pfisterer, M. Plante, and I. Vergote Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 2006 4699 4707
12. I. Vergote, N.J. Finkler, and J.B. Hall Randomised phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer Int J Gynecol Cancer 20 2010 772 780
13. J. Sehouli, D. Stengel, and G. Oskay-Oezcelik Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynaecological Oncology Ovarian Cancer Study Group J Clin Oncol 26 2008 3176 3182
14. W. ten Bokkel Huinink, S.R. Lane, and G.A. Ross Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma Ann Oncol 15 2004 100 103
15. W. Meier, A. du Bois, and A. Reuss Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomised phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) Gynecol Oncol 114 2009 199 205
16. C. Marth, J. Alexandre, and L.C. Hanker Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial J Clin Oncol 29 2011 (suppl.; abstr. 5052)
17. B.J. Monk, T.J. Herzog, and S.B. Kaye Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer J Clin Oncol 28 2010 3107 3114
18. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
19. Cancer Therapy Evaluation Program CTCfAE, Version 3.0. Published August 9, 2006. < http://ctep.cancer.gov/protocolDevelopment/electronic/ applications/ctc.htm#ctc/30 > [accessed October 29, 2010].
20. A. Poveda, I. Vergote, and S. Tjulandin Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial Ann Oncol 22 2010 39 48
21. M.A. Bookman Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy Oncologist 4 1999 87 94
22. Available from: < http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM171149.pdf >.
23. M.E. Gore, I. Fryatt, and E. Wiltshaw Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 1990 207 211
24. M. Markman, R. Rothman, and T. Hakes Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
25. M. Markman, A. Kennedy, and K. Webster Clinical features of hypersensitivity reactions to carboplatin J Clin Oncol 17 1999 1141
26. A. Poveda, R. Salazar, and J.M. del Campo Update in the management of ovarian and cervical carcinoma Clin Transl Oncol 9 2007 443 451
27. T.T. Nguyen, J.D. Wright, and M.A. Powell Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer Int J Gynecol Cancer 18 2008 1194 1199
28. < http://www.mango-group.it/images/protocolli/inovatyon/protocol/ synopsis/2010/10/14.pdf >; 2011 [accessed May 16, 2011].